RadNet to Acquire iCAD for $100 Million, Advancing AI-Powered Breast Cancer Detection
• RadNet Inc. has announced plans to acquire iCAD Inc. for approximately $100 million, uniting two leading companies in AI-powered cancer detection technology with a focus on breast cancer screening.
• The acquisition, unanimously approved by both companies' boards, is expected to close by Q3 2025 and aims to accelerate innovation in early cancer detection, improve radiologist workflow, and enhance patient outcomes.
• The combined entity will leverage RadNet's scale and clinical leadership with iCAD's AI solutions in breast cancer detection, risk evaluation, and density assessment to create a comprehensive platform for advancing population health initiatives.
iCad's AI-Powered Breast Cancer Detection Tech ProFound Detection version 4.0 Receives FDA Clearance
• iCad's ProFound Detection version 4.0, an AI-powered solution for digital breast tomosynthesis (DBT), has received FDA clearance, marking a significant advancement in cancer detection technology.
• The new version demonstrates a 22% overall improvement in detecting challenging cancer subtypes, including a 50% improvement in identifying cancers within dense breast tissue, enhancing early detection.
• ProFound Detection version 4.0 offers more precise lesion marking with an 18% overall improvement in cases with no marks, reducing false positives and providing clinicians with a more efficient AI concurrent-reader solution.
• iCad expects to expand the availability of ProFound Detection version 4.0 globally and to vendor-specific platforms in 2025, further solidifying its competitive position in cancer detection.
iCAD's ProFound Detection 4.0 Receives FDA Clearance for Enhanced Breast Cancer Detection
• iCAD's ProFound Detection Version 4.0, an AI-powered solution for digital breast tomosynthesis, has received FDA clearance, enhancing cancer detection and specificity.
• The new version demonstrates a 6.3% improvement in AUC, leading to better identification of aggressive cancers and a reduction in false positives.
• ProFound Detection 4.0 offers a 22% overall improvement in detecting challenging cancer subtypes, including a 50% improvement in dense breast tissue.
• Clinicians can now incorporate prior exams into the AI analysis, improving clinical accuracy and streamlining workflows for more informed decision-making.
© Copyright 2025. All Rights Reserved by MedPath